Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study

Zerbinati, Nicola; Esposito, Cristina; D’Este, Edoardo; Calligaro, Alberto; Valsecchi, R.

doi:10.1007/s13555-018-0226-5

Cited by 22 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Contact Sensitizersmentioning

confidence: 99%

“…Another contact sensitizer used as topical immunotherapy is dinitrochlorobenzene (DNCB) [140]. In a recent report, 50.98% of patients responded to DNCB, compared to 34.43% who responded to DPCP [140]. In the past DNCB has also shown positive results when tested for alopecia areata, totalis and universalis, and for different disease duration periods (Table 1) [22].…”

Section: Contact Sensitizersmentioning

confidence: 99%

See 1 more Smart Citation

Alopecia areata: A multifactorial autoimmune condition

Simakou

Butcher

Reid

et al. 2019

Journal of Autoimmunity

202

151

View full text Add to dashboard Cite

Highlights  Alopecia areata is a polygenic and multifactorial autoimmune disease characterised by non-scarring hair loss.  Autoreactive CD8 + , CD4 + , natural killer cells and plasmacytoid dendritic cells infiltrate around the hair follicles during the growth (anagen) phase.  Increased cytokine activity, particularly IFN-γ, results in disruption of the hair follicle immune privilege and premature termination of the anagen phase, followed by hair follicle atrophy and dystrophy in persistent disease.

show abstract

Section: Contact Sensitizersmentioning

confidence: 99%

Section: Contact Sensitizersmentioning

confidence: 99%

Alopecia areata: A multifactorial autoimmune condition

Simakou

Butcher

Reid

et al. 2019

Journal of Autoimmunity

202

151

View full text Add to dashboard Cite

show abstract

“…DPCP has also been shown to be well tolerated. 15 The main limitation of our study is the retrospective design.…”

Section: Discussionmentioning

confidence: 97%

Limited efficacy of diphenylcyclopropenone in the treatment of alopecia areata: Experience from a Tertiary Healthcare Institution in Singapore

Leong

Mok

Chandran

2020

Dermatologic Therapy

View full text Add to dashboard Cite

Alopecia areata (AA) is a common cause of nonscarring hair loss. Diphenylcyclopropenone (DPCP) is a form of contact immunotherapy used in the treatment of AA. We retrospectively reviewed all patients who were diagnosed with AA over a 4-year period (1st January 2012 to 31st December 2015) and who have received DPCP. Forty patients were studied in total. The mean duration of disease prior to the study was 195 days. Patients received a mean number of 14.91 sessions (range: 1-65). The mean number of sessions required before clinical response was seen was 2.33 sessions, corresponding to 0.001% DPCP. Based on the modified Global Assessment Grading System, 33.5% (n = 11) of the patients experienced less than 25% improvement, 48.5% (n = 16) experienced 25%-74% improvement and 18.3% (n = 6) experienced more than 75% improvement. One patient had severe sensitisation reaction amounting to near erythroderma which resolved completely upon cessation of DPCP therapy. No other adverse reactions were noted in the cohort. DPCP remains a valuable tool in a dermatologist's armamentarium in treating alopecia areata as it is safe, well-tolerated, and shows limited efficacy.

show abstract

“…Currently, the most widely used type B fillers are resorbable polyesters, such as PLA and poly(ε‐caprolactone) (PCL). In addition, fillers containing hydroxyapatite can be classified as type B as well . For example, Radiesse which is comprised hydroxyapatite and cellulose was approved by FDA in June 2015.…”

Section: Polymeric Injectable Fillersmentioning

confidence: 99%

Polymeric injectable fillers for cosmetology: Current status, future trends, and regulatory perspectives

Zhao

Zhang

et al. 2019

J of Applied Polymer Sci

View full text Add to dashboard Cite

Injectable fillers have become a vital part of cosmetology. A wide variety of injectable fillers are developed for either correction of facial wrinkles and folds or facial contouring. As the most popular filler products, polymeric injectable fillers represent a class of the most common implantable medical devices. This review is intended to not only present current filler products, but also share perspectives of future trends, development processes, and regulatory considerations for the next generation of fillers. First, currently approved polymeric injectable fillers are described in detail. Second, future trends of polymeric injectable fillers are discussed. Fillers based on the emerging technologies in tissue engineering and regenerative medicine with stimuli‐responsive or tunable properties, as well as device/drug combination products, are promising candidates. Third, fillers for cosmetology are different from traditionally recognized medical devices. As a result, the target population of such fillers is different from that of other implantable devices, leading to different user needs that impact their development processes. Last, product applications, regulatory requirements, device evaluation, characteristics, and difficulties for regulating filler products for minimally invasive cosmetology are reviewed. Both regulatory science and scientific supervision are needed for polymeric injectable fillers which are facing great opportunities as well as challenges. © 2019 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2020, 137, 48515.

show abstract

Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study

Cited by 22 publications

References 26 publications

Alopecia areata: A multifactorial autoimmune condition

Alopecia areata: A multifactorial autoimmune condition

Limited efficacy of diphenylcyclopropenone in the treatment of alopecia areata: Experience from a Tertiary Healthcare Institution in Singapore

Polymeric injectable fillers for cosmetology: Current status, future trends, and regulatory perspectives

Contact Info

Product

Resources

About